AbbVie Inc

ABBV

223.430USD

+4.410+2.01%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

AbbVie Inc's Score

Industry at a Glance

Industry Ranking

33 / 159

Overall Ranking

97 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

AbbVie Inc Highlights

StrengthsRisks

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 263.76%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 263.76%.

Overvalued

The company’s latest PE is 93.74, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.33B shares, increasing 0.10% quarter-over-quarter.

Held by Manning & Napier Group, LLC

Star Investor Manning & Napier Group, LLC holds 356.00 shares of this stock.

Analyst Rating

Based on 31 analysts

Buy

Current Rating

247.505

Target Price

+13.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of AbbVie Inc is 8.82, ranking 33 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 16.62B, representing a year-over-year increase of 10.04%, while its net profit experienced a year-over-year increase of 5775.00%.

Score

Industry at a Glance

Previous score

8.82

Change

0



Financials

5.37

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.72

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of AbbVie Inc is 5.05, ranking 153 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 93.74, which is 89.91% below the recent high of 178.02 and 76.81% above the recent low of 21.74.

Score

Industry at a Glance

Previous score

5.05

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 33/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of AbbVie Inc is 7.61, ranking 102 out of 159 in the Pharmaceuticals industry. The average price target is 245.00, with a high of 289.00 and a low of 187.64.

Score

Industry at a Glance

Previous score

7.61

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of AbbVie Inc is 9.21, ranking 36 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 234.05 and the support level at 208.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.54

Change

1.67

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of AbbVie Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 74.86%, representing a quarter-over-quarter decrease of 0.13%. The largest institutional shareholder is The Vanguard, holding a total of 179.94M shares, representing 10.18% of shares outstanding, with 3.86% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

176.93M

+0.24%

BlackRock Institutional Trust Company, N.A.

92.78M

+0.74%

State Street Investment Management (US)

79.82M

-0.25%

Geode Capital Management, L.L.C.

40.44M

+3.22%

JP Morgan Asset Management

36.42M

-2.81%

Charles Schwab Investment Management, Inc.

25.96M

-3.08%

Capital Research Global Investors

25.23M

-0.14%

Morgan Stanley Smith Barney LLC

23.97M

+1.96%

Norges Bank Investment Management (NBIM)

23.10M

-7.94%

Fidelity Management & Research Company LLC

19.95M

+1.53%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AbbVie Inc is 9.20, ranking 13 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

AbbVie Inc

ABBV

7.95 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment